Agios Pharmaceuticals Outperform Rating Reiterated at Royal Bank of Canada
AGIO Stock | USD 59.39 0.73 1.24% |
About 65% of all Agios Pharm's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Agios Pharm suggests that some traders are interested. Agios Pharm's investing sentiment overview a quick insight into current market opportunities from investing in Agios Pharm. Many technical investors use Agios Pharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Agios |
Royal Bank of Canada reiterated their outperform rating on shares of Agios Pharmaceuticals in a research report released on Thursday, Benzinga reports. Royal Bank of Canada currently has a 55.00 target price on the biopharmaceutical companys stock. Several other equities analysts also recently weighed in on AGIO. StockNews.com downgraded Agios Pharmaceuticals
Read at thelincolnianonline.com
Agios Pharm Current Investor Sentiment
Panic Vs Confidence
65
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Agios Pharm's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Agios Pharm.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
Agios Pharm Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Agios Pharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Agios Pharm Maximum Pain Price across 2024-12-20 Option Contracts
Agios Pharm's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Agios Pharm close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Agios Pharm's options.
Agios Pharm Fundamental Analysis
We analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Agios Pharm is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Agios Pharm Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Agios Pharm stock to make a market-neutral strategy. Peer analysis of Agios Pharm could also be used in its relative valuation, which is a method of valuing Agios Pharm by comparing valuation metrics with similar companies.
Peers
Agios Pharm Related Equities
CCCC | C4 Therapeutics | 8.59 | ||||
NRIX | Nurix Therapeutics | 4.15 | ||||
MRSN | Mersana Therapeutics | 4.11 | ||||
MGTX | MeiraGTx Holdings | 3.36 | ||||
BDTX | Black Diamond | 3.11 | ||||
ARVN | Arvinas | 2.85 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
PLRX | Pliant Therapeutics | 2.00 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
DAWN | Day One | 1.53 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
IDYA | Ideaya Biosciences | 1.37 | ||||
BPMC | Blueprint Medicines | 1.35 | ||||
SNDX | Syndax Pharmaceuticals | 1.27 | ||||
BMRN | Biomarin Pharmaceutical | 0.93 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
KALV | Kalvista Pharmaceuticals | 0.30 | ||||
ANAB | AnaptysBio | 0.64 | ||||
COGT | Cogent Biosciences | 0.73 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
KROS | Keros Therapeutics | 1.38 | ||||
RLAY | Relay Therapeutics | 2.08 |
Check out Agios Pharm Hype Analysis, Agios Pharm Correlation and Agios Pharm Performance. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.